118 related articles for article (PubMed ID: 24706167)
1. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.
Hertz DL; Roy S; Jack J; Motsinger-Reif AA; Drobish A; Clark LS; Carey LA; Dees EC; McLeod HL
Breast Cancer Res Treat; 2014 May; 145(1):245-54. PubMed ID: 24706167
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103.
Shen F; Jiang G; Philips S; Gardner L; Xue G; Cantor E; Ly RC; Osei W; Wu X; Dang C; Northfelt D; Skaar T; Miller KD; Sledge GW; Schneider BP
Clin Cancer Res; 2023 Jul; 29(13):2494-2500. PubMed ID: 37126018
[TBL] [Abstract][Full Text] [Related]
3. Differential methylation and expression of genes in the hypoxia-inducible factor 1 signaling pathway are associated with paclitaxel-induced peripheral neuropathy in breast cancer survivors and with preclinical models of chemotherapy-induced neuropathic pain.
Kober KM; Lee MC; Olshen A; Conley YP; Sirota M; Keiser M; Hammer MJ; Abrams G; Schumacher M; Levine JD; Miaskowski C
Mol Pain; 2020; 16():1744806920936502. PubMed ID: 32586194
[TBL] [Abstract][Full Text] [Related]
4. Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer.
Mortensen C; Steffensen KD; Simonsen E; Herskind K; Madsen JS; Olsen DA; Iversen DB; Bergmann TK; Pottegård A; Stage TB
Pain; 2023 Jul; 164(7):1502-1511. PubMed ID: 36508173
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin-aldosterone system inhibitors are associated with improved paclitaxel-induced peripheral neuropathy in lung cancer: a study using administrative claims data.
Ihara Y; Sawa K; Imai T; Kimura T; Otani M; Kawai R; Takatori S; Shintani A
Support Care Cancer; 2023 Nov; 31(12):730. PubMed ID: 38019339
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal rapamycin attenuates the mechanical hyperalgesia of paclitaxel-induced peripheral neuropathy in mice.
Lu ZP; Zou JQ; Lian WY; Lei HY; Xu SY
Neuroreport; 2023 Oct; 34(14):713-719. PubMed ID: 37556589
[TBL] [Abstract][Full Text] [Related]
7. CYP2C8 rs11572080 and CYP3A4 rs2740574 risk genotypes in paclitaxel-treated premenopausal breast cancer patients.
Attia HRM; Kamel MM; Ayoub DF; Abd El-Aziz SH; Abdel Wahed MM; El-Fattah SNA; Ablel-Monem MA; Rabah TM; Helal A; Ibrahim MH
Sci Rep; 2024 Apr; 14(1):7922. PubMed ID: 38575662
[TBL] [Abstract][Full Text] [Related]
8. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
Abraham JE; Guo Q; Dorling L; Tyrer J; Ingle S; Hardy R; Vallier AL; Hiller L; Burns R; Jones L; Bowden SJ; Dunn JA; Poole CJ; Caldas C; Pharoah PP; Earl HM
Clin Cancer Res; 2014 May; 20(9):2466-75. PubMed ID: 24599932
[TBL] [Abstract][Full Text] [Related]
9. An up-to-date view of paclitaxel-induced peripheral neuropathy.
Wu S; Xiong T; Guo S; Zhu C; He J; Wang S
J Cancer Res Ther; 2023 Dec; 19(6):1501-1508. PubMed ID: 38156915
[TBL] [Abstract][Full Text] [Related]
10. Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers.
Kim SH; Kim KH; Hyun JW; Kim JH; Seo SS; Kim HJ; Park SY; Lim MC
Front Oncol; 2022; 12():942960. PubMed ID: 36059704
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences.
Camara MD; Zhou Y; De Sousa TN; Gil JP; Djimde AA; Lauschke VM
Hum Genomics; 2024 Apr; 18(1):40. PubMed ID: 38650020
[TBL] [Abstract][Full Text] [Related]
12. Blockade of CCR5 suppresses paclitaxel-induced peripheral neuropathic pain caused by increased deoxycholic acid.
Zhong S; Liu F; Giniatullin R; Jolkkonen J; Li Y; Zhou Z; Lin X; Liu C; Zhang X; Liu Z; Lv C; Guo Q; Zhao C
Cell Rep; 2023 Nov; 42(11):113386. PubMed ID: 37948181
[TBL] [Abstract][Full Text] [Related]
13. The Safety and Efficacy of Cryotherapy in the Prevention of Paclitaxel-Induced Neuropathy: A Systematic Review.
Hossain MF; Kharel M; Rajib MH; Khan MA; Anwar MY; Lamsal Y; Aziz SN
Cureus; 2023 Aug; 15(8):e44026. PubMed ID: 37664355
[TBL] [Abstract][Full Text] [Related]
14. Translation of paclitaxel-induced peripheral neurotoxicity from mice to patients: the importance of model selection.
Cavaletti G; Alberti P; Canta A; Carozzi V; Cherchi L; Chiorazzi A; Crippa L; Marmiroli P; Meregalli C; Pozzi E; Rodriguez-Menendez V; Steinkühler C; Licandro SA
Pain; 2024 May; ():. PubMed ID: 38723182
[TBL] [Abstract][Full Text] [Related]
15. Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--response.
Guo Q; Abraham JE; Caldas C; Earl HM; Pharoah PP;
Clin Cancer Res; 2015 Jul; 21(13):3094. PubMed ID: 26133777
[No Abstract] [Full Text] [Related]
16. Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems.
Hu X; Jiang Z; Teng L; Yang H; Hong D; Zheng D; Zhao Q
Front Mol Biosci; 2021; 8():770808. PubMed ID: 34901160
[TBL] [Abstract][Full Text] [Related]
17. Just in time! Identification of a novel mechanism for treating PIPN.
Stratton H; Khanna R
J Physiol; 2020 Jun; 598(12):2283-2284. PubMed ID: 32266977
[No Abstract] [Full Text] [Related]
18. SNPs and taxane toxicity in breast cancer patients.
Bosó V; Herrero MJ; Santaballa A; Palomar L; Megias JE; de la Cueva H; Rojas L; Marqués MR; Poveda JL; Montalar J; Aliño SF
Pharmacogenomics; 2014; 15(15):1845-58. PubMed ID: 25495407
[TBL] [Abstract][Full Text] [Related]
19. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.
Rivera E; Cianfrocca M
Cancer Chemother Pharmacol; 2015 Apr; 75(4):659-70. PubMed ID: 25596818
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
Kendra KL; Plummer R; Salgia R; O'Brien ME; Paul EM; Suttle AB; Compton N; Xu CF; Ottesen LH; Villalona-Calero MA
Mol Cancer Ther; 2015 Feb; 14(2):461-9. PubMed ID: 25504632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
